A novel, actionable pathway promoting metastasis of triple negative breast cancer

三阴性乳腺癌(TNBC)特别具有侵袭性，缺乏有针对性的治疗，仅限于化疗。一种名为PEAK1的蛋白质驱动着TNBC，但一直是“无法下药”的。最近，我们发现了一种名为CAMK2D的酶，它作用于PEAK1的下游并介导其作用。在这项资助中，我们将描述CAMK2D的机制，并确定阻断其作用的药物的效果。这可能导致一种新的针对TNBC的靶向和个性化治疗。

Triple negative breast cancer (TNBC) is particularly aggressive and lacks targeted therapies, limiting treatment to chemotherapy. A protein termed PEAK1 drives TNBC but has remained 'undruggable'. Recently, we identified an enzyme, termed CAMK2D, that acts downstream of PEAK1 and mediates its effects. In this grant we will characterize the mechanism of CAMK2D and determine the effect of a drug that blocks its action. This may lead to a new targeted and personalized treatment for TNBC.